Subjective attitude to risperidone long-acting injectable (RLAI): Results from a long-term Italian study in subjects with schizophrenia or schizoaffective disorder

被引：0
|
作者：
Rossi, A. [1 ]
Bernareggi, M. M. [2 ]
Giustra, M. G. [2 ]
机构：
[1] Univ Laquilo, Dept Expt Med, Laquila, Italy
[2] Janssen Cilag SpA, Risperidone Long Acting Trial Italian Invest, Med Affairs, Milan, Italy
来源：
EUROPEAN PSYCHIATRY | 2008年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：S167 / S167
页数：1
相关论文
共 50 条
  • [1] Remission in schizophrenia: 1 year Italian study with risperidone long-acting injectable (RLAI) in subjects with schizophrenia or schizoaffective disorder
    Rossi, A.
    Bernareggi, M. M.
    Giustra, M. G.
    EUROPEAN PSYCHIATRY, 2008, 23 : S167 - S167
  • [2] Clinical maintenance response with risperidone long-acting injectable (rlai) in subjects with schizophrenia or schizoaffective disorder: A 52 weeks Italian study
    Rossi, A.
    Bernareggi, M. M.
    Giustra, M. G.
    EUROPEAN PSYCHIATRY, 2008, 23 : S167 - S168
  • [3] Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder
    Rossi, Alessandro
    Bagala, Anna
    Del Curatolo, Vincenzo
    Scapati, Francesco
    Bernareggi, Micaela Maria
    Giustra, Maria Grazia
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2009, 24 (07) : 574 - 583
  • [4] Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder
    Lindenmayer, Jean-Pierre
    Khan, Akbar
    Eerdekens, Marielle
    Van Hove, Ilse
    Kushner, Stuart
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 (02) : 138 - 144
  • [5] LONG-TERM REMISSION IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER: RESULTS FROM THE RISPERIDONE LONG-ACTING INJECTABLE VERSUS QUETIAPINE RELAPSE PREVENTION TRIAL (CONSTATRE)
    Smeraldi, E.
    Cavallaro, R.
    Smalc, V. Folnegovic
    Bidzan, L.
    Ceylan, E.
    Schreiner, A.
    Lex, A.
    EUROPEAN PSYCHIATRY, 2009, 24
  • [6] Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)
    Smeraldi, Enrico
    Cavallaro, Roberto
    Folnegovic-Smalc, Vera
    Bidzan, Leszek
    Ceylan, Mehmet Emin
    Schreiner, Andreas
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2013, 3 (04) : 191 - 199
  • [7] Obese patients with schizophrenia and schizoaffective disorder: Efficacy of injectable long-acting risperidone
    Permuy, RT
    Turner, MS
    Bouhours, P
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 175 - 175
  • [8] Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable
    Rosa, Fernanda
    Schreiner, Andreas
    Thomas, Pierre
    Sherif, Tarek
    CLINICAL DRUG INVESTIGATION, 2012, 32 (04) : 267 - 279
  • [9] Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable
    Fernanda Rosa
    Andreas Schreiner
    Pierre Thomas
    Tarek Sherif
    Clinical Drug Investigation, 2012, 32 : 267 - 279
  • [10] Descriptive study about long-acting injectable risperidone (RLAI) in outpatients
    Sala Cassola, R.
    Sobrino Cabra, O.
    Moreno Menguiano, C.
    EUROPEAN PSYCHIATRY, 2007, 22 : S165 - S166
12345